Assertio-Garda deal analysis: what the Rolvedon-focused takeover means for specialty pharma investors
Find out why Assertio is being sold to Garda Therapeutics and what the Rolvedon-focused deal means for specialty pharma strategy.
Why Vyome’s VT-1953 data could reshape supportive oncology care in advanced cancer wounds
Vyome’s VT-1953 heads to AACR 2026 with Phase 2 data in malignant fungating wounds. Read what this could change for supportive oncology.
Why MaaT Pharma’s MaaT013 survival signal could reshape refractory GI-aGvHD treatment debate
MaaT Pharma’s MaaT013 posted pivotal Phase 3 GI-aGvHD data. Read what it could mean for EMA approval, adoption, and microbiome therapeutics.
Can Hoth Therapeutics’s topical HT-001 redefine EGFR therapy adherence in cancer supportive care?
Hoth’s HT-001 showed 100% response in EGFR therapy toxicity trial. Learn what this means for cancer symptom relief, treatment continuity, and future trials.
FDA clears mAbxience–Amneal denosumab biosimilars, opening a new front in osteoporosis and oncology pricing
mAbxience and Amneal Pharmaceuticals have secured U.S. Food and Drug Administration (FDA) approval for two denosumab biosimilars, Boncresa and Oziltus, referencing Prolia and XGEVA respectively, clearing a long-anticipated regulatory hurdle in osteoporosis and oncology supportive care. The approvals position Amneal Pharmaceuticals as the exclusive U.S. commercial partner, with mAbxience responsible for development and manufacturing, marking […]